TOVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Theriva Biologics Inc (TOVX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks positive momentum, has weak financial performance, and no significant catalysts to drive growth in the near term. While technical indicators are neutral, the absence of strong trading signals or positive sentiment suggests holding off on investment for now.
The MACD is slightly positive, indicating weak bullish momentum, but the RSI is neutral at 51.964. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the pre-market price is below the pivot level of 0.191, suggesting a bearish trend. Support levels at 0.173 and 0.162 may provide some downside protection, but resistance at 0.21 and 0.221 indicates limited upside in the short term.
NULL identified. No recent news or significant trading trends from hedge funds or insiders. MACD is slightly positive, but not a strong signal.
is also down by 0.65%. Financial performance is weak, with a significant drop in EPS (-92.45% YoY) and net income (-21.16% YoY). Analysts have lowered the price target from $7 to $4, citing an increase in share count.
In Q4 2025, revenue remained at $0 with no growth. Net income dropped to -$3,506,000 (-21.16% YoY), and EPS fell to -0.12 (-92.45% YoY). Gross margin remains at 0%. Overall, financials indicate poor performance with no signs of growth.
Alliance Global maintains a Buy rating but has lowered the price target to $4 from $7 due to an increase in share count. This reflects reduced confidence in the stock's upside potential.
